The collaboration seeks to produce novel off-the-shelf TCR-based bispecific molecules designed to overcome current limitations in cell therapy approaches against solid tumors SAN DIEGO, Calif., and Singapore – December 21, 2023 – ImmunoScape, a biotechnology...
MiNK Therapeutics combines its unique, proprietary library of T-cell antigens with ImmunoScape’s cutting-edge platform for rapid discovery of novel T-cell receptors Therapeutic development to focus on novel cell therapies as well as bispecific immune cell...
Therapeutics for solid tumors remain in a nascent corner of cancer research despite representing 90% of all cancers in adults. Thirty years after the first Chimeric Antigen Receptor was reported, CAR-T cell therapies have seen significant breakthroughs managing liquid...
The ImmunoScape team is heading to the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco in a few weeks. Our CEO Choon-Peng (Choon) Ng, our Vice President, Discovery Dan MacLeod, and our Senior Director, Business Development Christopher Alfonso will be in...
ImmunoScape Appoints Systems Immunology and Computational Biology Expert Dr. John Tsang to its Scientific Advisory Board Expertise from award-winning computational biologist, human immunologist and engineer with experience from Yale, NIH, and NIAID will help advance...
